Agreement - June 30, 2020
BioArctic signs agreement with the University of Oslo
BioArctic and University of Oslo, Institute of Clinical Medicine (IKM), have signed a research collaboration agreement to increase the understanding of Apolipoprotein E (ApoE) as a drug target for Alzheimer’s disease. BioArctic will provide financial support for a two-year research position, with potential extension, and Professor Lars Nilsson at the Department of Pharmacology will be […]
Collaboration - December 19, 2019
BioArctic enters new collaboration with Eisai
BioArctic has announced the initiation of a research collaboration with Eisai aimed at further studying the profile of the investigational drug candidate BAN2401. The research collaboration with Eisai is in addition to the existing development and commercialization agreement for BAN2401. This new research collaboration is intended to further characterize the binding profile of BAN2401. “We […]
Clinical Trials - December 12, 2019
BioArctic’s partner Eisai presents new trial data
BioArctic has announced that data from the ongoing BAN2401 Phase 2b open-label extension study in early Alzheimer’s disease patients was presented by Eisai at the Clinical Trials in Alzheimer’s Disease (CTAD) conference in San Diego, US. A subset of patients from the core Phase 2b study enrolled in the open label extension study. The analysis […]
Business article - December 10, 2019
”A combination of great science, great projects and great people”
BioArctic’s lead compound has the potential to become the first disease-modifying treatment for Alzheimer’s, and so far the company’s journey has involved FDA approvals, a successful deal with AbbVie, collaborations with universities – and not least, the hiring of a very dedicated CEO. For years the treatments for central nervous system diseases such as Alzheimer’s […]
Global report - October 24, 2019
Biogen & Eisai revive plan for Alzheimer’s drug – positive news for BioArctic’s drug candidate
Biogen and Eisai will seek U.S. approval for the Alzheimer’s treatment aducanumab, which works on a similar principal as BioArctic’s BAN2401. Biogen and Eisai decided to end the two late-stage trials of aducanumab in March when a so-called “futility analysis” revealed the trials had little hope of succeeding, reports Reuters. However, Biogen has now said […]
Pharma Award - October 15, 2019
BioArctic’s CEO named “Pharmacist of the Year”
Sveriges Farmaceuter, a Swedish professional association for pharmacists, has chosen BioArctic’s CEO, Gunilla Osswald, as this year’s recipient of the “Pharmacist of the Year” award. This recognition has been awarded annually since 1983 by the association’s Board of Directors to a pharmacist active in Sweden who has helped to reinforce, develop or consolidate the role […]